Cover Image
市場調查報告書

Telormedix SA的產品平台分析

Telormedix SA - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 253684
出版日期 內容資訊 英文 24 Pages
訂單完成後即時交付
價格
Back to Top
Telormedix SA的產品平台分析 Telormedix SA - Product Pipeline Review - 2015
出版日期: 2015年06月24日 內容資訊: 英文 24 Pages
簡介

Telormedix SA,是進行癌症及感染疾病治療藥的開發的生物醫藥品企業。

本報告提供Telormedix SA的產品開發平台的現狀及各開發階段比較分析、藥物簡介、開發平台的分析與最新趨勢等資訊。

Telormedix SA的基本資料

Telormedix SA概要

  • 主要資訊
  • 企業資料

Telormedix SA:R&D概要

  • 主要的治療範圍

Telormedix SA:開發平台的檢討

  • 各開發階段的開發中產品
  • 單劑產品

Telormedix SA:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Telormedix SA:藥物簡介

  • imiquimod
  • TMX-201
  • TMX-202
  • TMX-302

Telormedix SA:開發平台分析

  • 各標靶
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Telormedix SA:最近的開發平台趨勢

Telormedix SA:總公司和子公司的所在地

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07150CDB

Summary

Global Markets Direct's, 'Telormedix SA - Product Pipeline Review - 2015', provides an overview of the Telormedix SA's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Telormedix SA's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Telormedix SA including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Telormedix SA's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Telormedix SA's pipeline products

Reasons to buy

  • Evaluate Telormedix SA's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Telormedix SA in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Telormedix SA's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Telormedix SA and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Telormedix SA
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Telormedix SA and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Telormedix SA Snapshot
    • Telormedix SA Overview
    • Key Information
    • Key Facts
  • Telormedix SA - Research and Development Overview
  • Key Therapeutic Areas
  • Telormedix SA - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Telormedix SA - Pipeline Products Glance
    • Telormedix SA - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Telormedix SA - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Telormedix SA - Drug Profiles
    • imiquimod
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TMX-201
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TMX-202
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • TMX-302
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Telormedix SA - Pipeline Analysis
    • Telormedix SA - Pipeline Products by Target
    • Telormedix SA - Pipeline Products by Route of Administration
    • Telormedix SA - Pipeline Products by Molecule Type
    • Telormedix SA - Pipeline Products by Mechanism of Action
  • Telormedix SA - Recent Pipeline Updates
  • Telormedix SA - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Telormedix SA, Key Information
  • Telormedix SA, Key Facts
  • Telormedix SA - Pipeline by Indication, 2015
  • Telormedix SA - Pipeline by Stage of Development, 2015
  • Telormedix SA - Monotherapy Products in Pipeline, 2015
  • Telormedix SA - Phase II, 2015
  • Telormedix SA - Preclinical, 2015
  • Telormedix SA - Pipeline by Target, 2015
  • Telormedix SA - Pipeline by Route of Administration, 2015
  • Telormedix SA - Pipeline by Molecule Type, 2015
  • Telormedix SA - Pipeline Products by Mechanism of Action, 2015
  • Telormedix SA - Recent Pipeline Updates, 2015

List of Figures

  • Telormedix SA - Pipeline by Top 10 Indication, 2015
  • Telormedix SA - Pipeline by Stage of Development, 2015
  • Telormedix SA - Monotherapy Products in Pipeline, 2015
  • Telormedix SA - Pipeline by Top 10 Target, 2015
  • Telormedix SA - Pipeline by Top 10 Route of Administration, 2015
  • Telormedix SA - Pipeline by Top 10 Molecule Type, 2015
  • Telormedix SA - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top